An observational study in Acute Liver Failure, sponsored by Li-Ying Sun. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Li-Ying Sun · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Acute liver failure (ALF) is a rare but life-threatening condition with high mortality. Despite advances in supportive care and liver transplantation, prognosis varies significantly across etiologies, particularly in patients with indeterminate causes.
This study aims to investigate the dynamic changes of clinical and biochemical indicators, identify potential etiologies-especially in indeterminate ALF-and evaluate prognostic risk factors. A dynamic prediction model will be developed to optimize clinical decision-making, including liver transplantation timing.
Both retrospective and prospective cohorts will be included. Multi-omics analyses (including transcriptomics, proteomics, metabolomics, and metagenomic sequencing) will be performed on liver tissue and biological samples to explore disease mechanisms and etiology.
96 studies on the registry are indexed under Liver Failure, Acute; 20 are open to participants now.
This study's planned enrollment of 400 is above the median of 112 across 34 observational studies indexed under Liver Failure, Acute.
Browse Liver Failure, Acute studies →This is the only study on the registry with Li-Ying Sun as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study population consists of patients diagnosed with acute liver failure who are treated at Beijing Friendship Hospital, Capital Medical University. Both adult and pediatric patients meeting established diagnostic criteria for acute liver failure will be included.
The study includes two cohorts: a retrospective cohort of patients treated between November 2016 and February 2026, and a prospective cohort of newly diagnosed patients enrolled from March 2026 onward.
Patients will be followed longitudinally to evaluate clinical outcomes, including survival, liver transplantation, and transplant-free survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults: Acute onset without pre-existing liver disease, development of hepatic encephalopathy ≥ grade II within 4 weeks Pediatrics: Acute onset (\<26 weeks), no chronic liver disease, coagulopathy not corrected by vitamin K: ≥1.5 with encephalopathy OR; INR >2 regardless of encephalopathy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Survival
Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)
Transplant-Free Survival
Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3)
Liver Transplantation Rate
Time frame: Up to 3 years after enrollment (every 3 months during the first year, then annually until year 3
Etiologic features identified by multi-omics analysis
Etiologic features in participants with acute liver failure will be assessed through multi-omics analyses of biospecimens, including liver tissue obtained from resected diseased liver during surgery (approximately 3 cm³) or from one ultrasound-guided liver biopsy core (approximately 2 cm in length), together with blood, urine, and stool samples. Multi-omics testing includes transcriptomic sequencing, proteomic analysis, metabolomic analysis, and metagenomic sequencing.
Time frame: From enrollment to completion of biospecimen collection and etiologic multi-omics assessment, up to 7 days
Short-Term Mortality
Time frame: 90 days after enrollment
Development of Prognostic Prediction Model
A prognostic model will be developed using clinical variables, laboratory parameters, and dynamic changes over time. Multivariable logistic regression and receiver operating characteristic (ROC) curve analysis will be used to evaluate model performance, including discrimination and calibration.
Time frame: Up to 3 years after enrollment
Change in alanine aminotransferase (ALT) over time
Serial serum ALT measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in aspartate aminotransferase (AST) over time
Serial serum AST measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in total bilirubin over time
Serial total bilirubin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in international normalized ratio (INR) over time
Serial INR measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in prothrombin time (PT) over time
Serial PT measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in serum creatinine over time
Serial serum creatinine measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in C-reactive protein (CRP) over time
Serial serum C-reactive protein measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in direct bilirubin over time
Serial direct bilirubin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in prothrombin activity (PTA) over time
Serial prothrombin activity (PTA) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in blood ammonia over time
Serial blood ammonia measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in blood phosphorus over time
Serial blood phosphorus measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in white blood cell count (WBC) over time
Serial white blood cell count (WBC) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in red blood cell count (RBC) over time
Serial red blood cell count (RBC) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in hemoglobin (HGB) over time
Serial hemoglobin (HGB) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in platelet count (PLT) over time
Serial platelet count (PLT) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in D-dimer over time
Serial D-dimer measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in serum albumin over time
Serial serum albumin measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in arterial lactate over time
Serial arterial lactate measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in blood glucose over time
Serial blood glucose measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in arterial pH over time
Serial arterial pH measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in CD4+ T-cell count over time
Serial CD4+ T-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in CD8+ T-cell count over time
Serial CD8+ T-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in CD19+ B-cell count over time
Serial CD19+ B-cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in CD56+ natural killer cell count over time
Serial CD56+ natural killer cell count measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in CD4+/CD8+ ratio over time
Serial CD4+/CD8+ ratio measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in immunoglobulin M (IgM) over time
Serial serum immunoglobulin M (IgM) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in immunoglobulin G (IgG) over time
Serial serum immunoglobulin G (IgG) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in immunoglobulin A (IgA) over time
Serial serum immunoglobulin A (IgA) measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in complement C3 over time
Serial serum complement C3 measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
Change in complement C4 over time
Serial serum complement C4 measurements will be obtained every 48 hours from admission until discharge to assess dynamic changes during hospitalization.
Time frame: Every 48 hours from admission to discharge, assessed up to 30 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2036, 129 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.